Hart Carl L, Gunderson Erik W, Perez Audrey, Kirkpatrick Matthew G, Thurmond Andrew, Comer Sandra D, Foltin Richard W
Department of Psychiatry, Division on Substance Abuse, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Neuropsychopharmacology. 2008 Jul;33(8):1847-55. doi: 10.1038/sj.npp.1301578. Epub 2007 Sep 12.
Intranasal methamphetamine abuse has increased dramatically in the past decade, yet only one published study has investigated its acute effects under controlled laboratory conditions. Thus, the current study examined the effects of single-dose intranasal methamphetamine administration on a broad range of behavioral and physiological measures. Eleven nontreatment-seeking methamphetamine abusers (two females, nine males) completed this four-session, in-patient, within-participant, double-blind study. During each session, one of four intranasal methamphetamine doses (0, 12, 25, and 50 mg/70 kg) was administered and methamphetamine plasma concentrations, cardiovascular, subjective, and psychomotor/cognitive performance effects were assessed before drug administration and repeatedly thereafter. Following drug administration, methamphetamine plasma concentrations systematically increased for 4 h postdrug administration then declined. Methamphetamine dose dependently increased cardiovascular measures and 'positive' subjective effects, with peaks occurring approximately 5-15 min after drug administration, when plasma levels were still ascending. In addition, cognitive performance on less complicated tasks was improved by all active methamphetamine doses, whereas performance on more complicated tasks was improved only by the intermediate doses (12 and 25 mg). These results show that intranasal methamphetamine produced predictable effects on multiple behavioral and physiological measures before peak plasma levels were observed. Of interest is the dissociation between methamphetamine plasma concentrations with cardiovascular measures and positive subjective effects, which might have important implications for potential toxicity after repeated doses.
在过去十年中,鼻内甲基苯丙胺滥用现象急剧增加,但仅有一项已发表的研究在受控实验室条件下调查过其急性影响。因此,本研究考察了单剂量鼻内给予甲基苯丙胺对一系列行为和生理指标的影响。11名未寻求治疗的甲基苯丙胺滥用者(2名女性,9名男性)完成了这项为期四阶段的住院、受试者内、双盲研究。在每个阶段,给予四种鼻内甲基苯丙胺剂量(0、12、25和50 mg/70 kg)中的一种,并在给药前以及给药后多次评估甲基苯丙胺血浆浓度、心血管、主观以及精神运动/认知表现方面的影响。给药后,甲基苯丙胺血浆浓度在给药后4小时内系统性升高,随后下降。甲基苯丙胺剂量依赖性地增加心血管指标和“积极的”主观效应,峰值出现在给药后约5 - 15分钟,此时血浆水平仍在上升。此外,所有有效甲基苯丙胺剂量均改善了较简单任务的认知表现,而较复杂任务的表现仅在中等剂量(12和25 mg)时得到改善。这些结果表明,在观察到血浆峰值水平之前,鼻内甲基苯丙胺对多种行为和生理指标产生了可预测的影响。有趣的是,甲基苯丙胺血浆浓度与心血管指标和积极主观效应之间存在分离,这可能对重复给药后的潜在毒性具有重要意义。